Search
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an
beta-Naphthoflavone
go.drugbank.com/drugs/DB06732Experimentalβ-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Alobresib
go.drugbank.com/drugs/DB14970InvestigationalAlobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998]
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.
Iodoform
go.drugbank.com/drugs/DB13813ApprovedInvestigationalVet approvedWithdrawnSince the beginning of the 20th century, iodoform has been commonly used as a healing and antiseptic dressing or powder for wounds and sores, however such clinical use to this date is limited.
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalApproximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigationalretains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after another ROS1 inhibitor has failed rather than as
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalGuselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade...